Home-Based Cancer Care Report

The Home-Based Cancer Care report views cancer care at home as a growing trend in the market. The report provides background on this area of the market as well as a look at some of the leading providers of home-based cancer care.

Get this free report

Pharmacy in LTC 2019 Report

Buy the Full Report

Top 60 Employer Profiles Report 2019

Buy the Full Report

Achieve measurable success in the increasingly complex and rapidly changing world of healthcare today. AMI’s experienced leadership team has developed free white papers to help businesses better understand the challenges while offering new strategies and alternative approaches to help drive measurable success.

Get Download

Now available:

White Paper: Understanding Prior Authorization Challenges and Opportunities

This Free White Paper Uncovers New Strategies to Help Identify Measurable Value, Effective Drug Utilization and Control Costs for Healthcare Stakeholders.

Find out what’s going on behind the curtain of prior authorization for the medical and pharmacy benefit in our free white paper “Prior Authorization in Today’s Healthcare Dynamic Marketplace.”

Learn More

White Paper: Bend the Curve

A New Era for the Management of Specialty Pharmaceuticals

Biologic, biotechnology-based, rare disease, or high-cost pharmaceuticals — collectively known as specialty drugs — can be covered under the pharmacy benefit, the medical benefit, or both depending on the benefit design plan sponsors require of the third-party administrator (including the pharmacy benefit manager – PBM; administrative service organization – ASO; or any administrator of a medical or pharmacy benefit).

Click here and download the white paper.

On average, up to 50% of specialty drugs today are covered under the medical benefit.

With the exception of a few key therapy areas, traditional tools used to manage specialty drugs under the medical benefit, such as prior authorizations and medical benefit carve-outs (i.e., “white-bagging”), have yielded limited value to plan sponsors.

This thought leadership analysis, with insights from recognized industry experts, will provide an overview of the challenges, a summary of the key issues plan sponsors must address and insights into best practices through an innovative new approach, Medical Benefit Drug Management (MBM).

Get Download

Top 10 Healthcare Market Trends in 2017

Published in American Health & Drug Benefits
February 2017

Written by Access Market Intelligence Principals John Santilli, MBA, and F. Randy Vogenberg, RPh, PhD

2016 saw a “pause” in most market trends as the US presidential election cycle unfolded and Brexit occurred. 2017 began with new leadership in Washington, DC, led by outsider President Donald Trump. Change is imminent throughout all segments of the US market.

How will the new policy leaders affect the healthcare landscape, and in which ways will that alter efforts for your organization can be gleaned from top-line insights on the coming changes?

This market trends overview briefly covers changes expected to emerge throughout 2017, covering areas such as:

  • Affordable Care Act and repeal
  • Changes in physicians’ payment
  • Emerging care models
  • High-value care
  • Payer changes

Download PDF